Close Menu
Home › Lynparza Delays Progression in Metastatic Pancreatic Cancer Patients With Germline BRCA Mutations

Lynparza Delays Progression in Metastatic Pancreatic Cancer Patients With Germline BRCA Mutations

Jun 03, 2019
|
Andrea Anderson
Premium

CHICAGO (GenomeWeb) – A clinical trial of a PARP inhibitor in metastatic pancreatic cancer patients has yielded "practice changing" results, according to some oncologists, and will likely lead to more widespread testing for germline mutations in the inherited cancer risk genes BRCA1 and BRCA2.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
03
Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Precision Oncology Specialties

  1. USPSTF Formalizes Slightly Expanded BRCA Screening Recommendations

  2. Lexent Bio Details Liquid Biopsy Monitoring Method, Expects Clinical Launch Next Year

    Premium

  3. Xylonix, BioGemex Ink MOU to Develop Point-of-Care Cancer Immunotherapy-Response Diagnostic

  4. New FDA Program May Help Oncologists Access Investigational Drugs in Precision Medicine Era

    Premium

  5. Liquid Biopsy Study Investigates Treatment for Breast Cancer Patients With Acquired HER2 Mutations

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.